Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board

Former Global Oncology Head from Sanofi-Aventis Joins the Nanobiotix Team

PARIS--()--Nanobiotix (Euronext: NANO / ISIN: FR0011341205), the oncology focused nanomedicine company, announced today that Dr. Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun in their roles, as part of a planned Supervisory Board succession.

Dr. Herrera joins Nanobiotix Supervisory Board with more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Before setting up his own oncology consultancy – Alain Oncologie Consulting (AOC) -, he headed the Oncology business at Sanofi-Aventis for ten years, where he was Vice President for the Global Oncology Business Strategy and Development (2007-2008) and Head of the Global Oncology Franchise (1998-2007). He contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®). His previous responsibilities within the pharmaceutical industry included the roles of Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.

Dr. Herrera said: “Over recent years, Nanobiotix’s nanomedicine technology has repeatedly demonstrated its significant potential for optimizing the efficacy of radiotherapy, a treatment currently used for about 60% of cancer patients and a key component of the treatment strategy in curative setting. I'm both delighted and privileged to be able to play a part in helping Nanobiotix to deliver its objectives and to overcome the challenges that lie ahead. I look forward to working with the Nanobiotix team.”

“We welcome Dr. Alain Herrera to the Supervisory Board. Pioneer of industrial oncology, his business and pharmaceutical industry experience will add important expertise to the Board,” said Laurent Levy, CEO of Nanobiotix. “Alain has been a member of the Scientific Advisory Board of Nanobiotix over the past years, so he already has a thorough knowledge of its business and its technology. We believe his skills and oncology leadership will assist us in fulfilling our strategic business objectives and to progress our international development.”

Laurent Levy added: "I would also like to thank Thierry Chopin and Isabelle Bou Antoun for the contribution they have made over the last years of service, helping to position Nanobiotix for a promising future."

The nomination of Dr. Herrera will be submitted to the approval of the next general shareholders’ meeting in accordance with applicable law.

About NANOBIOTIX www.nanobiotix.com

Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the efficacy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital world-wide.

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. Nanobiotix' objective is to enhance its leading position in the nanomedicine field on the main oncology markets. Its pipeline of universal products enable to target the major indications of cancers (breast cancer, prostate cancer, lung cancer…), leading to a potential market of several billion dollars. Thanks to the physical based mechanism of action of its nanoparticles, Nanobiotix brings out a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN Code: FR0011341205, Euronext mnemonic code: NANO, Bloomberg code: NANO: FP).

Contacts

Nanobiotix
Laurent Levy, +33 (0)1 40 26 07 55
CEO
laurent.levy@nanobiotix.com
or
NewCap.
Financial communication and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh, +33 (0)1 44 71 98 53
lvdelouvrier@newcap.fr
or
Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec, +33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59
afloyer@yucatan.fr
or
College Hill
Media relations (Europe excl. France)
Melanie Toyne Sewell / Anastasios Koutsos / Donia Al Saffar, +44 (0) 207 457 2020
nanobiotix@collegehill.com

Release Summary

Nanobiotix appoints Dr. Alain Herrera to the Supervisory Board

Sharing

Contacts

Nanobiotix
Laurent Levy, +33 (0)1 40 26 07 55
CEO
laurent.levy@nanobiotix.com
or
NewCap.
Financial communication and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh, +33 (0)1 44 71 98 53
lvdelouvrier@newcap.fr
or
Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec, +33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59
afloyer@yucatan.fr
or
College Hill
Media relations (Europe excl. France)
Melanie Toyne Sewell / Anastasios Koutsos / Donia Al Saffar, +44 (0) 207 457 2020
nanobiotix@collegehill.com